10.1016/s0140-6736(20)30734-0 - Carfilzomib, dexamethasone, and darat...

This document has been corrected

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

10.1016/s0140-6736(20)30734-0

Published Online: 2020-07-?

Journal: The Lancet•Publisher: Elsevier BV

Authors: Anita Zahlten-Kumeli•David Siegel•Hang Quach•Hui Yang•Katja Weisel•Maria-Victoria Mateos•Meletios Dimopoulos•Ola Landgren•Saad Z Usmani•Xavier Leleu•Zandra Klippel

This document has been corrected

10.1016/s0140-6736(20)30734-0

Published Online: 2020-07-?

Journal: The Lancet

Authors: Anita Zahlten-Kumeli•David Siegel•Hang Quach•Hui Yang•Katja Weisel•Maria-Victoria Mateos•Meletios Dimopoulos•Ola Landgren•Saad Z Usmani•Xavier Leleu•Zandra Klippel

NOW

2020-08-15•Erratum

Department of Error

10.1016/s0140-6736(20)31669-x

* information provided by CrossRef

2020-08-15•Erratum

10.1016/s0140-6736(20)31669-x

* information provided by CrossRef

2020-07-?•Published

This document has been corrected

10.1016/s0140-6736(20)30734-0

Published Online: 2020-07-?

Journal: The Lancet•Publisher: Elsevier BV

Authors: Anita Zahlten-Kumeli•David Siegel•Hang Quach•Hui Yang•Katja Weisel•Maria-Victoria Mateos•Meletios Dimopoulos•Ola Landgren•Saad Z Usmani•Xavier Leleu•Zandra Klippel